Piper Sandler on Amgen (AMGN): 'Another Clinical Win For The Oncology Franchise'
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $328.00 price target on Amgen (NASDAQ: AMGN).The analyst commented: "Another ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
